4.8 Article

Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation

Journal

SCIENCE
Volume 320, Issue 5876, Pages 667-670

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1156037

Keywords

-

Funding

  1. NCRR NIH HHS [P20 RR016462, P20 RR021905, P20 RR015557, P20 RR15557, P20 RR16462] Funding Source: Medline
  2. NIAID NIH HHS [R01 AI051454-03, R01 AI051454-02, R01 AI051454-05, R01 AI051454-01A1, R01 AI051454-04, R01 AI051454] Funding Source: Medline

Ask authors/readers for more resources

Glycogen synthase kinase 3 beta (GSK3 beta) is involved in metabolism, neurodegeneration, and cancer. Inhibition of GSK3 beta activity is the primary mechanism that regulates this widely expressed active kinase. Although the protein kinase Akt inhibits GSK3 beta by phosphorylation at the N terminus, preventing Akt- mediated phosphorylation does not affect the cell- survival pathway activated through the GSK3 beta substrate beta- catenin. Here, we show that p38 mitogen- activated protein kinase ( MAPK) also inactivates GSK3 beta by direct phosphorylation at its C terminus, and this inactivation can lead to an accumulation of beta- catenin. p38 MAPK- mediated phosphorylation of GSK3 beta occurs primarily in the brain and thymocytes. Activation of beta- catenin- mediated signaling through GSK3 beta inhibition provides a potential mechanism for p38 MAPK- mediated survival in specific tissues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available